15 completed, 5 recruiting, 4 terminated, 2 unknown. 26 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 26 | Completed 15, Recruiting 5, Terminated 4, Unknown 2 |
Follow Carcinoma, Renal Cell: new trials by email Literature Review of Carcinoma, Renal Cell trials Research Report on Carcinoma, Renal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-24 | 2026-10-16 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma cabozantinib and nivolumab - Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma | Phase 4 | Recruiting | Centre Francois Baclesse | 83 | 2025-10-01 | 2026-07-14 |
| Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy - Renal Cell Cancer, Kidney Neoplasm | Phase 4 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 409 | 2025-06-15 | 2025-07-03 |
| Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma Nivolumab, Cabozantinib - Kidney Cancer, Renal Cell Cancer | Phase 4 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 50 | 2025-05-16 | 2025-09-24 |
| OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Olaparib, Lenvatinib, Sunitinib - Renal Cell Carcinoma, Ovarian Carcinoma | Phase 4 | Unknown | University Medical Center Groningen | 30 | 2024-05-01 | 2023-11-29 |
| Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) Contrast enhanced ultrasound with Lumason - Renal Malignant Tumor | Phase 4 | Terminated | Indiana University | 12 | 2019-07-16 | 2024-10-10 |
| A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Nivolumab, Ipilimumab - Renal Cell Carcinoma | Phase 4 | Completed | Bristol-Myers Squibb | 211 | 2017-01-16 | 2022-11-01 |
| An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Nivolumab - Renal Cell Carcinoma | Phase 4 | Completed | Bristol-Myers Squibb | 197 | 2016-01-08 | 2022-10-27 |
| Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Pazopanib, Sunitinib - Metastatic Renal Cell Cancer | Phase 4 | Completed | Institut Claudius Regaud | 47 | 2015-11-17 | 2026-03-31 |
| Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Everolimus - Renal Cell Carcinoma | Phase 4 | Terminated | Mario Negri Institute for Pharmacological Research | 31 | 2015-07-01 | 2018-02-05 |
| Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Everolimus (RAD001) - Metastatic Renal Cell Carcinoma (mRCC) | Phase 4 | Completed | Novartis Pharmaceuticals | 29 | 2012-05-21 | 2017-07-19 |
| First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Pazopanib - Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell | Phase 4 | Completed | iOMEDICO AG | 44 | 2012-01-24 | 2017-08-23 |
| Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Sunitinib, Erlotinib, Midazolam - Non Small-cell Lung Cancer, Renal-cell Cancer | Phase 4 | Completed | Markus Joerger | 54 | 2012-01-01 | 2016-02-02 |
| Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Everolimus - Metastatic Renal Cell Carcinoma | Phase 4 | Completed | Kidney Cancer Research Bureau | 37 | 2011-11-01 | 2014-02-06 |
| Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Everolimus - Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy | Phase 4 | Completed | iOMEDICO AG | 64 | 2011-03-01 | 2017-11-14 |
| A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. RAD001 - Renal Cell Carcinoma | Phase 4 | Completed | Novartis Pharmaceuticals | 143 | 2009-11-11 | 2019-06-24 |
| Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Sunitinib (SUTENT) - Metastatic Renal Cell Carcinoma | Phase 4 | Terminated | Assistance Publique - Hôpitaux de Paris | 33 | 2008-12-01 | 2015-04-01 |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors usage oral angiogenesis inhibitor, stop oral angiogenesis inhibitor - Renal Cell Carcinoma, Gastrointestinal Stromal Tumor | Phase 4 | Unknown | Radboud University Medical Center | 30 | 2008-10-01 | 2011-09-16 |
| Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Aldesleukin - Metastatic Renal Cell Carcinoma, Metastatic Melanoma | Phase 4 | Completed | Novartis Pharmaceuticals | 26 | 2008-09-03 | 2021-06-08 |
Showing 20 of 26. Sign in to see all of them.
Kidney Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (4) · Carcinoma, Hepatocellular (3) · Neoplasm Metastasis (3) · Esophageal Neoplasms (2) · Gastrointestinal Stromal Tumors (2) · Head and Neck Neoplasms (2) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Liver Neoplasms (2) · Melanoma (2)
Adenocarcinoma (26) · Carcinoma (26) · Female Urogenital Diseases (26) · Female Urogenital Diseases and Pregnancy Complications (26) · Kidney Diseases (26) · Male Urogenital Diseases (26) · Neoplasms by Histologic Type (26) · Neoplasms by Site (26) · Neoplasms, Glandular and Epithelial (26) · Urogenital Diseases (26) · Urogenital Neoplasms (26) · Urologic Diseases (26) · Urologic Neoplasms (26) · Neoplasms (25) · Kidney Neoplasms (17)
Everolimus (5) · Nivolumab (5) · Sunitinib (5) · pazopanib (3) · aldesleukin (2) · cabozantinib (2) · Bupropion (1) · Caffeine (1) · Counseling (1) · Early Intervention, Educational (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · Gene Expression Profiling (1) · High-Energy Shock Waves (1) · Immune Checkpoint Inhibitors (1)
Novartis Pharmaceuticals (4) · Bristol-Myers Squibb (2) · iOMEDICO AG (2) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · Case Comprehensive Cancer Center (1) · Centre Francois Baclesse (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fox Chase Cancer Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Indiana University (1) · Institut Claudius Regaud (1) · Kidney Cancer Research Bureau (1) · Lisa Sanderson Cox, PhD (1) · Mario Negri Institute for Pharmacological Research (1)
United States (10) · France (4) · Germany (4) · Italy (2) · Netherlands (2) · Russia (2) · Algeria (1) · China (1) · Egypt (1) · India (1) · Jordan (1) · Lebanon (1) · Saudi Arabia (1) · South Africa (1) · Switzerland (1)
Cindy Connell, MD, PhD (1) · Esther Broekman, MD (1) · Jordan Swennson, MD (1) · Lisa S. Cox, PhD (1) · Markus Joerger, MD PhD (1) · Michael Staehler, Dr. med (1) · Michael Staehler, PD MD (1)
PMID 21266057, PMID 21775497, PMID 22241828, PMID 22704310, PMID 23733379, PMID 25466382, PMID 27101285, PMID 32738823, PMID 33070307, PMID 33300144, PMID 34611902, PMID 34791718, PMID 35210307, PMID 36104138, PMID 37230961, PMID 39868569, PMID 41801644, PMID 42433301
2015 (1), R01CA091912 (1)